Drug Trial Radar · NCT07828197
A Pharmacokinetic Study of HDM1005 Injection at Different Injection Sites
Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
135
Planned (sponsor's estimate)
Start
Sep 3, 2026
Primary completion
Oct 2026
Study completion Nov 2026
Sponsor
- Lead sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the relative bioavailability of a single subcutaneous injection of HDM1005 solution at different injection sites (upper arm and thigh)by using the abdomen subcutaneous injection as a control.
Conditions
- Overweight and/or Obesity
- Healthy Participants
Interventions
HDM1005Drug
2.0 mg, SC, single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: Up to Day 29
- AUC(0-t)Time frame: Up to Day 29
- AUC(0-∞)Time frame: Up to Day 29
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital of Anhui Medical University
Hefei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.